EMA limits use of JAK inhibitors for at-risk groups in wake of safety concerns
Following the US’ lead, the EMA is cutting back on the use of JAK inhibitors for some patients over a suite of safety concerns.
The EMA’s safety committee issued new guidance on Friday, recommending that a group of JAK inhibitors used for chronic inflammatory disorders are only used in certain at-risk patients if no alternatives are available.
That includes patients 65 years and older, those at risk of major heart problems, those who smoke or who have extensively in the past and those at risk of cancer. Patients at risk of blood clots in the lungs and deep veins (VTE) should take caution, the committee says, while recommending lower doses for some patients at risk of VTE, cancer or major heart problems.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
